amylin long acting (AZD6234) / AstraZeneca - LARVOL DELTA

SELENE 2: A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight (clinicaltrials.gov) - P3 | N=1500 | Recruiting | Sponsor: AstraZeneca | Not yet recruiting ➔ Recruiting

Enrollment open • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

SELENE 3: A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus (clinicaltrials.gov) - P3 | N=500 | Recruiting | Sponsor: AstraZeneca | Not yet recruiting ➔ Recruiting

Enrollment open • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

SELENE 1: A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus (clinicaltrials.gov) - P3 | N=2500 | Recruiting | Sponsor: AstraZeneca

New P3 trial • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

SELENE 2: A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight (clinicaltrials.gov) - P3 | N=1500 | Not yet recruiting | Sponsor: AstraZeneca

New P3 trial • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

AZD6234: safety and efficacy in phase 1 and phase 2 trials (EASD 2026) - No abstract available

Clinical • P1 data • P2 data • Diabetes • Metabolic Disorders • Obesity

SELENE 3: A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus (clinicaltrials.gov) - P3 | N=500 | Not yet recruiting | Sponsor: AstraZeneca

New P3 trial • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

A Study to Assess the Relative Bioavailability of Different Subcutaneous Formulations ofAZD6234 (clinicaltrials.gov) - P1 | N=19 | Active, not recruiting | Sponsor: AstraZeneca | Recruiting ➔ Active, not recruiting

Enrollment closed • Genetic Disorders • Obesity

Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early-Phase Clinical Trials. (PubMed, Diabetes Obes Metab) - "Amylin-based therapies represent a promising addition to the evolving treatment landscape of obesity. Their emerging efficacy as both standalone and combination therapies supports a multi pathway approach to addressing the biological complexity and heterogeneity of the disease."

Journal • Genetic Disorders • Obesity

APRICUS: A Study in Participants With Obesity or Overweight With at Least One Weight-related Comorbidity (clinicaltrials.gov) - P2 | N=262 | Completed | Sponsor: AstraZeneca | Trial primary completion date: Aug 2025 ➔ Dec 2025

Trial primary completion date • Genetic Disorders • Obesity

This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / Overweight (clinicaltrials.gov) - P2 | N=14 | Active, not recruiting | Sponsor: AstraZeneca | Not yet recruiting ➔ Active, not recruiting | N=871 ➔ 14

Enrollment change • Enrollment closed • Genetic Disorders • Obesity

CONTEMPO: A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and Overweight (clinicaltrials.gov) - P1/2 | N=166 | Active, not recruiting | Sponsor: AstraZeneca | Recruiting ➔ Active, not recruiting

Enrollment closed • Monotherapy • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus • DPP4

A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity (clinicaltrials.gov) - P1 | N=50 | Recruiting | Sponsor: AstraZeneca | Trial completion date: Dec 2026 ➔ Jul 2027 | Trial primary completion date: Dec 2026 ➔ Jul 2027

Trial completion date • Trial primary completion date • Genetic Disorders • Obesity

ASCEND: A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone (clinicaltrials.gov) - P2 | N=377 | Completed | Sponsor: AstraZeneca | Active, not recruiting ➔ Completed

Trial completion • Genetic Disorders • Obesity

A Study to Assess the Relative Bioavailability of Different Subcutaneous Formulations ofAZD6234 (clinicaltrials.gov) - P1 | N=21 | Recruiting | Sponsor: AstraZeneca | Active, not recruiting ➔ Recruiting

Enrollment open • Genetic Disorders • Obesity

CONTEMPO: A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and Overweight (clinicaltrials.gov) - P1/2 | N=160 | Recruiting | Sponsor: AstraZeneca | Active, not recruiting ➔ Recruiting | N=118 ➔ 160

Enrollment change • Enrollment open • Monotherapy • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus • DPP4

A Study to Assess the Relative Bioavailability of Different Subcutaneous Formulations ofAZD6234 (clinicaltrials.gov) - P1 | N=21 | Active, not recruiting | Sponsor: AstraZeneca | Trial completion date: Mar 2026 ➔ Apr 2027 | Trial primary completion date: Mar 2026 ➔ Sep 2026

Trial completion date • Trial primary completion date • Genetic Disorders • Obesity

A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234 (clinicaltrials.gov) - P1 | N=28 | Recruiting | Sponsor: AstraZeneca

New P1 trial • Hepatology

A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity (clinicaltrials.gov) - P1 | N=50 | Recruiting | Sponsor: AstraZeneca | N=75 ➔ 50

Enrollment change • Genetic Disorders • Obesity

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD6234 After Repeat Dose Administration in Participants Who Are Overweight or Obese (clinicaltrials.gov) - P1 | N=104 | Completed | Sponsor: AstraZeneca | Active, not recruiting ➔ Completed

Trial completion • Genetic Disorders • Obesity

A Study to Assess the Relative Bioavailability of Different Subcutaneous Formulations ofAZD6234 (clinicaltrials.gov) - P1 | N=19 | Active, not recruiting | Sponsor: AstraZeneca | Not yet recruiting ➔ Active, not recruiting

Enrollment closed • Genetic Disorders • Obesity

Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes. (PubMed, Peptides) - "The first therapeutically useful amylin receptor (AMYR) agonist, pramlintide was based upon the structure of non-aggregating rat amylin and found limited application as an adjunct to insulin therapy...Amongst these agents is the dual AMYR/ calcitonin-receptor (CTR) agonist, cagrilintide that has also been co-formulated into a once weekly subcutaneous injection with the long-acting glucagon-like peptide-1receptor (GLP-1R) agonist, semaglutide (CagriSema)...Several recently developed long-acting amylin analogues have shown strong efficacy as monotherapy in clinical trials: these include eloralintide, petrelintide, Met-233 and AZD6234...Gastrointestinal side effects, especially nausea, similar to those reported for GLP-1R agonists are commonplace during initiation and up-titration of amylin analogues but mostly resolve during continued use. Evidence is emerging that long-acting AMYR agonists may show potential therapeutic benefits in treatment of patients with fatty liver..."

Journal • Review • Cardiovascular • Diabetes • Genetic Disorders • Hepatology • Hypertension • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity (clinicaltrials.gov) - P1 | N=75 | Recruiting | Sponsor: AstraZeneca | N=50 ➔ 75

Enrollment change • Genetic Disorders • Obesity

ARAY: Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist (clinicaltrials.gov) - P2 | N=69 | Active, not recruiting | Sponsor: AstraZeneca | Recruiting ➔ Active, not recruiting

Enrollment closed • Diabetes • Endocrine Disorders • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

...AstraZeneca’s broader weight loss portfolio also includes the long-acting amylin AZD6234, which is due to read out phase 2 data in the first half of 2026. (FierceBiotech) - "Meanwhile, a phase 2 study of a combination of AZD6234 with the dual GLP-1 and glucagon agonist AZD9550 is due to read out in the second half of the year."

P2 data • Obesity

A Study to Investigate the Effect of AZD6234 and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity (clinicaltrials.gov) - P1 | N=50 | Recruiting | Sponsor: AstraZeneca | Trial completion date: Jul 2026 ➔ Dec 2026 | Trial primary completion date: Jul 2026 ➔ Dec 2026

Trial completion date • Trial primary completion date • Genetic Disorders • Obesity